ClinicalTrials.gg
RecruitingNCT03382938Updated Mar 19, 2025

Dexmedetomidine Wound Infiltration in Cesarean Section

An interventional study of Dexmedetomidine and Ropivacaine in Postoperative Pain, sponsored by Attikon Hospital. Recruiting at 1 site in Greece. Open to female participants aged 18 Years to 40 Years. Per ClinicalTrials.gov, last updated 2025-03-19.

Sponsored by Attikon Hospital · Not applicable, Interventional, and Prevention

From the registry’s dates

  • Primary completion was expected by Dec 2025, 10 months ago, but the record still lists the study as recruiting.
  • Started Aug 2019; still recruiting 7 years 2 months later.
Phase
Not applicable
Study type
Interventional
Enrollment
100
Allocation
Randomized
Ages
18 Years to 40 Years
Sex
Female
01

Study summary

The effects of four different wound infiltration protocols in cesarean section will be investigated on parturient' pain intensity, PCA morphine consumption given, side effects and parturient' overall satisfaction.

One group will receive for wound infiltration dexmedetomidine, the second ropivacaine, the third dexmedetomidine combined with ropivacaine, while the last one will receive normal saline (placebo group).

Read the detailed description

Parturients undergoing scheduled cesarean section under combined spinal-epidural anesthesia will be included in the study. Women will be randomly allocated according to the type of the solution used for wound infiltration into one of the following four groups using the closed envelop method.

Group DEX: Following the closure of the uterine incision and the rectus fascia, 20 mL solution of dexmedetomidine 1γ/kg within Normal Saline will be infiltrated subcutaneously along the skin wound edges.

Group ROPI: Following the closure of the uterine incision and the rectus fascia, 20 mL solution of ropivacaine 0.375% will be infiltrated subcutaneously along the skin wound edges.

Group DEX-ROPI: Following the closure of the uterine incision and the rectus fascia, 20 mL solution of dexmedetomidine 1γ/kg within ropivacaine 0.375% will be infiltrated subcutaneously along the skin wound edges.

Placebo Group: Following the closure of the uterine incision and the rectus fascia, 20 ml with 0.9 % saline solution will be infiltrated subcutaneously along the skin wound edges.

In Postanesthesia Care Unit, 2 mg of morphine will be administered bolus epidurally before the removal of the epidural catheter. Postoperative analgesia will be managed with the systematic administration of intravenous paracetamol 1g x 3 /day, oral celecoxib 200mg x 2 /day and PCA morphine (1 mg/ml) (setting: bolus dose 1 ml every 7 min). The total morphine consumption 24 hours after the PCA device initiation will be recorded.

Also, ranitidine 50 mg and metoclopramide 10 mg will be given intravenously twice per day, while ondansetron 4 mg will be prescribed to be administered intravenously in case of postoperative nausea or vomiting (max x 3 times/day).

Postoperative pain will be assessed in rest and mobilization using the Visual Analogue Scale (VAS, 0-10) at 1, 3, 6, 12, 18 and 24 hours after the end of surgery from an anesthesiologist who does not know the group assignment. Also, at the same time points, hemodynamic parameters of the parturients, side effects (nausea, vomiting, sedation, pruritus) and complications (fever, infection in the area of the wound infiltration, bleeding) will be recorded, while 24 hours postoperatively the overall patient' satisfaction with her postoperative analgesia management will be assessed using a 4 point scale.

02

Conditions studied

  • Postoperative Pain

Browse trials for

Keywords

  • dexmedetomidine
  • ropivacaine
  • wound infiltration
  • ceasarean section
03

In context

Pain, Postoperative

5,640 studies on the registry are indexed under Pain, Postoperative; 1,230 are open to participants now.

This study's planned enrollment of 100 is above the median of 75 across 4,821 interventional studies indexed under Pain, Postoperative.

Browse Pain, Postoperative studies →

Lead sponsor

Attikon Hospital is the lead sponsor of 86 studies on the registry; 17 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 40 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • pregnancy >37 weeks, , \<35

Exclusion criteria

Exclusion Criteria:

  • patient refusal, epilepsy, GERD, morbid obesity, drug allergy, >2, presence of atrioventricular block, severe systemic disease, multiple gestation, high risk pregnancy, to epidural technique, a history of severe systemic disease, recreational drug or alcohol use
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ASA physical status

The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Investigator, Outcomes assessor)
Enrollment
100 participants (estimated)

Study arms

  • Active comparator
    Dexmedetomidine

    Drug: dexmedetomidine (Dexmed) 20 mL solution of dexmedetomidine used for wound infiltration

    Drug: Dexmedetomidine

  • Active comparator
    Ropivacaine

    Drug: ropivacaine 20 mL solution of ropivacaine 0.375% used for wound infiltration

    Drug: Ropivacaine

  • Active comparator
    Dexmedetomidine - Ropivacaine

    Drug: dexmedetomidine (Dexmed) combined with Drug: ropivacaine 20 mL solution of dexmedetomidine 1γ/kg within ropivacaine 0.375% used for wound infiltration

    Drug: Dexmedetomidine - Ropivacaine

  • Placebo comparator
    0.9 % saline

    Drug:0.9 % saline solution (Normal saline). 20 ml with 0.9 % saline solution used for wound infiltration

    Other: 0,9% saline

Interventions

  • WOUND INFILTRATION IN CESAREAN SECTION

    Also known as: Dexmed

  • WOUND INFILTRATION IN CESAREAN SECTION

    Also known as: Ropi

  • DrugDexmedetomidine - Ropivacaine

    WOUND INFILTRATION IN CESAREAN SECTION

    Also known as: Dexmed Ropi

  • Other0,9% saline

    placebo WOUND INFILTRATION IN CESAREAN SECTION

    Also known as: normal saline

06

What researchers measure

Primary outcomes

  1. Pain score

    Postoperative pain will be assessed in rest and mobilization using the Visual Analogue Scale (VAS, 0-10)

    Time frame: up to 24 hours after the end of surgery

Secondary outcomes

  1. morphine consumption

    morphine given by PCA (1 mg/ml)(setting: bolus dose 1 ml every 7 min).

    Time frame: 24 hours after the PCA device initiation will be recorded

  2. overall patient satisfaction

    overall patient satisfaction with postoperative analgesia using a 4 point scale

    Time frame: 24 hours after the end of surgery

07

Study locations

1 of 1 sites recruiting
  • Paraskevi K Matsota
    Athens, Other 13231, Greece
    Recruiting
    • Paraskevi K Matsota, Assoc Prof · Contactmatsota@yahoo.gr · 00306945544563
    • Paraskevi Mastota, MD, PhD · Principal investigator
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2019 (actual). Primary completion is estimated for Dec 2025, 75 months after the start.

Of 2,089 non-industry interventional studies with no phase under Pain, Postoperative, half reached primary completion within 11 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 23. This study's planned 75 months is above that.

Counting every sponsor, half of 2,102 studies reached it within 11 months; a quarter within 6 and three quarters within 23.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 17, 2017
First posted
Dec 26, 2017
StartActual
Aug 23, 2019
Primary completionEst.
Dec 20, 2025
CompletionEst.
Nov 20, 2026
Last update
Mar 19, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 19, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03382938
Lead sponsor
Attikon Hospital
Responsible party
Paraskevi Matsota (Assoc Prof of Anaesthesiology, Attikon Hospital) — Principal investigator
First posted
Dec 26, 2017
Start date
Aug 23, 2019
Primary completion
Dec 20, 2025 (estimated)
Completion
Nov 20, 2026 (estimated)
Last update
Mar 19, 2025

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Dexmedetomidine · Ropivacaine

Start the discussion